63.25

3.27% -2.14

After Hours: 62.70 -0.55 -0.87%

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $63.25, with a volume of 518.33K. It is down -3.27% in the last 24 hours and down -16.26% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Previous Close:

$65.39

Open:

$65.85

24h Volume:

518.33K

Relative Volume:

1.00

Market Cap:

$2.68B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-13.63

EPS:

-4.64

Net Cash Flow:

$-123.00M

1W Performance:

+2.03%

1M Performance:

-16.26%

6M Performance:

+23.15%

1Y Performance:

+20.87%

1-Day Range:

$62.15

$66.40

1-Week Range:

$62.15

$67.70

52-Week Range:

$38.51

$85.25

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

323

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	63.25	2.78B	17.39M	-135.89M	-123.00M	-4.64
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Nov-20-25	Initiated	Mizuho	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-27-25	Resumed	H.C. Wainwright	Buy
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Feb 11, 2026

Why is Tarsus Pharmaceuticals Inc stock going down2025 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn

Feb 11, 2026

Feb 10, 2026

Panic Selling: Is Tarsus Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Levels & Reliable Intraday Trade Plans - baoquankhu1.vn

Feb 10, 2026

Feb 07, 2026

Federated Hermes Inc. Has $905,000 Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Feb 07, 2026

Feb 06, 2026

Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price - simplywall.st

Feb 06, 2026

Feb 05, 2026

Liquidity Mapping Around (TARS) Price Events - Stock Traders Daily

Feb 05, 2026

Feb 03, 2026

Dow Update: Does Tarsus Pharmaceuticals Inc have declining or rising EPS2025 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn

Feb 03, 2026

Feb 01, 2026

Stocks to watch: Tarsus Pharmaceuticals sees RS rating rise to 81 - MSN

Feb 01, 2026

Jan 31, 2026

Lisanti Capital Growth LLC Has $2.56 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Jan 31, 2026

Jan 30, 2026

Tarsus prices $125M stock offering - MSN

Jan 30, 2026

Does Tarsus Pharmaceuticals Inc have declining or rising EPSBuy Signal & Intraday High Probability Setup Alerts - baoquankhu1.vn

Jan 30, 2026

Jan 29, 2026

Will Tarsus Pharmaceuticals Inc. benefit from green energy policies2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru

Jan 29, 2026

Investors Still Waiting For A Pull Back In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - 富途牛牛

Jan 29, 2026

Tarsus Pharmaceuticals Shares Show Resilience Amid Market Pressure - AD HOC NEWS

Jan 29, 2026

Jan 28, 2026

Hussman Strategic Advisors Inc. Purchases Shares of 31,500 Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Jan 28, 2026

Volume Report: How does DMC Global Inc correlate with Nasdaq2025 Major Catalysts & Weekly Top Gainers Trade List - baoquankhu1.vn

Jan 28, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Jan 28, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Jan 28, 2026

Jan 27, 2026

Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Jan 27, 2026

Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - Finviz

Jan 27, 2026

Jan 26, 2026

SG Americas Securities LLC Sells 27,833 Shares of Tarsus Pharmaceuticals, Inc. $TARS - Defense World

Jan 26, 2026

Jan 25, 2026

Why (TARS) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jan 25, 2026

Jan 24, 2026